Ahmad Najem

1.1k total citations
30 papers, 669 citations indexed

About

Ahmad Najem is a scholar working on Molecular Biology, Oncology and Surgery. According to data from OpenAlex, Ahmad Najem has authored 30 papers receiving a total of 669 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 15 papers in Oncology and 6 papers in Surgery. Recurrent topics in Ahmad Najem's work include Melanoma and MAPK Pathways (12 papers), Cancer-related Molecular Pathways (5 papers) and Cutaneous Melanoma Detection and Management (4 papers). Ahmad Najem is often cited by papers focused on Melanoma and MAPK Pathways (12 papers), Cancer-related Molecular Pathways (5 papers) and Cutaneous Melanoma Detection and Management (4 papers). Ahmad Najem collaborates with scholars based in Belgium, United States and France. Ahmad Najem's co-authors include Mohammad Krayem, Fabrice Journé, Ahmad Awada, Ghanem Ghanem, Ghanem E. Ghanem, Anne Perdrix, Sven Saussez, Jean‐Christophe Marine, François Salès and William E. Neville and has published in prestigious journals such as SHILAP Revista de lepidopterología, Nature Cell Biology and Cancer.

In The Last Decade

Ahmad Najem

30 papers receiving 659 citations

Peers

Countries citing papers authored by Ahmad Najem

Since Specialization

Citations

This map shows the geographic impact of Ahmad Najem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ahmad Najem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ahmad Najem more than expected).

Fields of papers citing papers by Ahmad Najem

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ahmad Najem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ahmad Najem. The network helps show where Ahmad Najem may publish in the future.

Co-authorship network of co-authors of Ahmad Najem

This figure shows the co-authorship network connecting the top 25 collaborators of Ahmad Najem. A scholar is included among the top collaborators of Ahmad Najem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ahmad Najem. Ahmad Najem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy 2024 ·Cancer Cell International ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Bertrand Blankert, Ahmad Najem, Ghanem Ghanem, Sven Saussez, Fabrice Journé	7
2	Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies 2023 ·Cells ·Ahmad Najem, Mohammad Krayem, (unknown), (unknown), Fabrice Journé, Ahmad Awada, Laurent Désaubry, Ghanem E. Ghanem	5
3	Macrophage Profiling in Head and Neck Cancer to Improve Patient Prognosis and Assessment of Cancer Cell–Macrophage Interactions Using Three-Dimensional Coculture Models 2023 ·International Journal of Molecular Sciences ·(unknown), Fabrice Journé, Ahmad Najem, (unknown), (unknown), Didier Dequanter, Sven Saussez, Géraldine Descamps	6
4	Synthesis and Characterization Some of Metals (ƖƖ) Complexes' with Mixed Ligands of saccharinate and Isatin Schiff Base 2023 ·SHILAP Revista de lepidopterología ·(unknown), Ahmad Najem, (unknown)	1
5	The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanoma 2023 ·Frontiers in Medicine ·(unknown), Ahmad Najem, (unknown), (unknown), (unknown), Fabrice Journé, Ahmad Awada, Dirk Van Gestel, Ghanem E. Ghanem, Mohammad Krayem	4
6	Development of fluorizoline analogues as prohibitin ligands that modulate C-RAF signaling, p21 expression and melanogenesis 2022 ·European Journal of Medicinal Chemistry ·(unknown), Hussein Abou‐Hamdan, Hajime Yurugi, (unknown), (unknown), Ahmad Najem, Ghanem E. Ghanem, Susumu Nakata, Krishnaraj Rajalingam, Peng Yu, Dong Wang, Canan G. Nebigil, Laurent Désaubry	3
7	Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit 2021 ·Molecular Cancer Research ·(unknown), Mohammad Krayem, Ahmad Najem, François Salès, Wilson H. Miller, Sonia V. del Rincón, Ahmad Awada, (unknown), Fabrice Journé	4
8	Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value 2021 ·Frontiers in Oncology ·Ahmad Najem, Jasper Wouters, Mohammad Krayem, Florian Rambow, (unknown), François Salès, Ahmad Awada, Stein Aerts, Fabrice Journé, Jean‐Christophe Marine, Ghanem E. Ghanem	8
9	Abstract 1082: Regorafenib resistance is associated with senescence-like phenotype and EMT in colorectal cancer (CRC) 2021 ·Cancer Research ·(unknown), Mohammad Krayem, Nadège Kindt, Ahmad Najem, Caroline Vandeputte, Fabrice Journé, Ahmad Awada, Ghanem E. Ghanem, Alain Hendlisz	1
10	Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance 2020 ·Cancers ·Mohammad Krayem, Philippe Aftimos, Ahmad Najem, (unknown), (unknown), (unknown), Rik de Wijn, Riet Hilhorst, Rob Ruijtenbeek, (unknown), Joseph Kerger, Ahmad Awada, Fabrice Journé, Ghanem Ghanem	15
11	Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma 2020 ·Nature Cell Biology ·Jasper Wouters, Zeynep Kalender Atak, Liesbeth Minnoye, Katina I. Spanier, Maxime De Waegeneer, Carmen Bravo González‐Blas, David Mauduit, Kristofer Davie, Gert Hulselmans, Ahmad Najem, Michael Dewaele, Dennis Pedri, Florian Rambow, Samira Makhzami, Valerie Christiaens, Frederik Ceyssens, Ghanem Ghanem, Jean‐Christophe Marine, Suresh Poovathingal, Stein Aerts	137
12	The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma 2019 ·Cancers ·Mohammad Krayem, (unknown), Ahmad Najem, An Wouters, Filip Lardon, Stéphane Simon, François Salès, Fabrice Journé, Ahmad Awada, Ghanem Ghanem, Dirk Van Gestel	20
13	Targeting prohibitin with small molecules to promote melanogenesis and apoptosis in melanoma cells 2018 ·European Journal of Medicinal Chemistry ·(unknown), Mohammad Krayem, Ahmad Najem, (unknown), Thierry Cresteil, Canan G. Nebigil, Dong Wang, Peng Yu, Embarek Bentouhami, Ghanem E. Ghanem, Laurent Désaubry	31
14	PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies 2017 ·Cancers ·Anne Perdrix, Ahmad Najem, Sven Saussez, Ahmad Awada, Fabrice Journé, Ghanem Ghanem, Mohammad Krayem	91
15	P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition 2017 ·European Journal of Cancer ·Ahmad Najem, Mohammad Krayem, François Salès, Nader Hussein, Bassam Badran, Caroline Robert, Ahmad Awada, Fabrice Journé, Ghanem E. Ghanem	41
16	New Drug Combination Strategies in Melanoma: Current Status and Future DirectionsNew Drug Combination Strategies in Melanoma: Current Status and Future Directions 2017 ·Anticancer Research ·Ahmad Najem, Mohammad Krayem, Anne Perdrix, Joseph Kerger, Ahmad Awada, Fabrice Journé, Ghanem Ghanem	28
17	p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib 2016 ·European Journal of Cancer ·Mohammad Krayem, Fabrice Journé, Murielle Wiedig, Renato Morandini, Ahmad Najem, François Salès, Léon C.L.T. van Kempen, Catherine Sibille, Ahmad Awada, Jean‐Christophe Marine, Ghanem Ghanem	45
18	The Muir-Torre Syndrome: A Disease of Sebaceous and Colonic Neoplasms 1989 ·Dermatology ·Robert A. Schwartz, David Goldberg, (unknown), (unknown), (unknown), Ahmad Najem, Philip Cohen	34
19	Comparative study of cefotetan and cefoxitin in the treatment of intra-abdominal infections 1988 ·American Journal of Obstetrics and Gynecology ·Ronald T. Lewis, Richard J. Duma, Roger Echols, Joseph G. Jemsek, Ahmad Najem, Robert Press, H. Harlan Stone, (unknown), Samuel E. Wilson	9
20	Cephalosporin therapy in intraabdominal infections 1988 ·The American Journal of Surgery ·Samuel E. Wilson, John A. Boswick, Richard J. Duma, Roger Echols, Joseph G. Jemsek, Robert Lerner, Ronald T. Lewis, Ahmad Najem, Robert Press, Max S. Rittenbury, H. Harlan Stone, (unknown)	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact